Loading...
Latest Update
Developing products that are first-in-class with unique mechanism of action and are different from those of existing therapies
Welcome to Pharmazz, Inc.
Pharmazz, Inc. is a visionary biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for critical care medicine. Founded and led by Professor Dr. Anil Gulati, a distinguished pharmacologist, inventor, and academic, Pharmazz is making groundbreaking advances in neurovascular pharmacology to address major unmet medical needs worldwide.
Our Mission & Leadership
At Pharmazz, we are driven by a commitment to scientific excellence and patient-centric innovation. Under the stewardship of experienced professionals, Pharmazz has successfully bridged the gap between complex pharmacology and life-saving clinical applications.
Innovative Pipeline & Therapeutic Focus
Pharmazz focuses heavily on the development of Endothelin-B receptor agonists and resuscitative agents designed to treat critical, life-threatening conditions:
- Sovateltide:A novel, first-in-class neurovascular agent currently undergoing the global Phase 3 clinical trial (RESPECT-ETB) across 81 sites worldwide. In India, sovateltide has reached a significant commercial milestone, having successfully treated over 120,000 patients suffering from ischemic stroke.
- Centhaquine: A highly effective resuscitative agent developed to treat hypovolemic shock. Centhaquine works through a precise mechanism of action that enhances venous return, effectively returning blood to active circulation to stabilize critically ill patients. Centhaquine is directly marketed and commercialized by Pharmazz.
Global Impact and Future Horizons
With a robust operational presence that spans international borders, the company is poised for significant global expansion. Through rigorous clinical trial methodology, regulatory diligence, and a passion for discovery, Pharmazz, Inc. continues to redefine the standard of care in critical and acute medicine.
More About UsProduct Pipeline
| Indication | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | Market | |
|---|---|---|---|---|---|---|
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
| India | U.S. |
Hypovolemic Shock
Centhaquine (Lyfaquin®) is a novel, first-in-class resuscitative agent for the treatment of hypovolemic shock...
Read More
Septic
Shock
Septic shock is defined as a life-threatening organ dysfunction caused by a dysregulated host response to ...
Read More
Acute Kidney Injury
Acute kidney injury (AKI) is a common complication in critically ill patients and is associated with increased...
Read More
Cardiac
Arrest
An experimental study was performed using an established model of cardiac arrest. Cardiopulmonary...
Read More
Cerebral Ischemic Stroke
Stroke is an important cause of serious long-lasting disability. Ischemic stroke caused by arterial occlusion...
Read More
Alzhieimer's Disease
Alzheimer s disease is the sixth-leading cause of death in the United States. An estimated 5.3 million Americans...
Read More
Acute Spinal Cord Injury
It is now known that progenitor stem cells are present in the spinal cord.Exposure of cultured neural progenitor cells to hypoxia also...
Read More
Management
The management team is well balanced with significant drug development and clinical expertise, and commercialization experience. In addition to the management and development team in the US, the company has over 80 employees through its subsidiary in India.
More Details
Dr. Gulati is leading clinical development and commercialization of first-in-class drug products in critical care medicine. He led the discovery, development and launch of Lyfaquin for hypovolemic shock & Tyvalzi for cerebral stroke.
Dr. Neil Marwah is a seasoned, entrepreneurial healthcare executive with more than 30 years of experience. His experience includes private practice, ancillary healthcare services, large provider organizations, private equity, and senior management at Global 500 enterprise.
Dr. McDonnell received his undergraduate degree from Georgetown University and his MD in 1985 from Northwestern University. Dr. McDonnell has also received postgraduate training in Emergency and Internal Medicine at Northwestern University.
Mr. Costello brings about 20 years of accounting, budgeting, audit preparation, reporting and financial modeling experience to Pharmazz. He served as Controller for Julian Toft and Downey, Inc. and as Vice President in Transwestern Commercial Real Estate's
Dr. Gulati has more than 38 years of experience and knowledge in starting and running medium sized organizations. He is the founding member of Pharmazz India Private Limited and is managing and operating the company since its inception.
Press Releases
Media Coverage
CHI Memorial First In Region To Enroll Patient In Groundbreaking Stroke Clinical Trial
CHI Memorial is proud to announce it is the first hospital in the world to enroll a patient in a Phase 3 clinical trial evaluating a promising new treatment for ischemic stroke. This groundbreaking...
Pharmazz, Inc. showcased the groundbreaking potential of its lead drug, Sovateltide
Pharmazz, Inc., a biopharmaceutical company addressing the critical care market, showcased the groundbreaking potential of its lead drug...
Pharmazz Chairman and CEO Dr. Anil Gulati’s IPC-IPSCON 2024 session sheds
By APN News On Nov 30, 2024 -- Pharmazz, Inc., a late-stage biopharmaceutical company addressing the critical care market, showcased the groundbreaking...
